Arrow Electronics and SiMa.ai Enter Distribution Agreement in EMEA
28.5.2024 18:00:00 EEST | Business Wire | Press release
Global technology provider Arrow Electronics and SiMa.ai, the software centric, embedded edge machine learning system-on-chip company, have entered into a strategic collaboration, enabling Arrow to distribute SiMa.ai products in the EMEA region.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240528873376/en/
SiMa.ai’s Machine Learning System-on-Chip MLSoC (Photo: Business Wire)
SiMa.ai delivers one platform for all edge AI that scales with customers as their AI/ML projects evolve, from computer vision, to transformers to multimodal generative AI. The SiMa.ai MLSoC (Machine Learning System on Chip) enables full pipeline deployment of complete real-world workloads as a standalone edge-based system, with high performance and power efficiency.
SiMa.ai’s MLSoC works seamlessly with Palette Software to support customers across multiple verticals such as industrial manufacturing, retail, aerospace, defense, agriculture, and healthcare, with increased compute capabilities, while maximizing efficiency by delivering the highest frames per second per watt (FPS/W) performance in the edge AI/ML market.
With this agreement, Arrow and SiMa.ai will jointly market SiMa.ai’s offerings and Arrow will serve as the region’s exclusive distributor for the SiMa.ai MLSoC, SiMa.ai Palette Software and SiMa.ai Development Kits.
Margit Tischler, vice president of engineering in EMEA for Arrow, said, “At Arrow, we recognise the importance of artificial intelligence at the edge. SiMa.ai extends our AI line card, allowing us to offer our customers a solution tailored to their specific AI needs.”
“We are pleased to enter this distribution agreement with Arrow, which will speed access for customers throughout Europe and the Middle East to SiMa.ai’s one platform for all edge AI — and will support customers as their AI/ML journeys evolve — from computer vision to transformers to multimodal generative AI,” said Elizabeth Samara-Rubio, chief business officer, SiMa.ai. “This agreement with Arrow will help SiMa.ai scale further to meet rising customer demand as organizations increasingly need a partner to help them deploy and scale AI/ML workloads at the edge.”
Arrow will showcase SiMa.ai in its booth (at Stand J1) at Hardware Pioneers Max in London from 28 to 29 May, 2024. In addition, SiMa.ai will be participating in a talk with Arrow at Hardware Pioneers Max titled, “Accelerate the Entire Vision Pipeline,” which will explore the practical roadmap of machine learning and AI in key end applications on 29.5.24 in Conference Room 1, from 10:40 - 11:10.
For more information on how SiMa.ai can help accelerate edge ML projects, prospective customers can register for the Arrow webinar featuring SiMa.ai on 10th June, 2024 by clicking here or book an AI Consultation with Arrow Experts.
About Arrow Electronics:
Arrow Electronics guides innovation forward for thousands of leading technology manufacturers and service providers. With 2023 sales of $33 billion, Arrow develops technology solutions that help improve business and daily life. Learn more at arrow.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240528873376/en/
Contact information
Thorsten Hecking
thorsten.hecking@arrow.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces 24-Week Long-Term Data from Phase 3 TRuE-AD4 Trial of Opzelura ® (ruxolitinib) Cream in Adults with Moderate Atopic Dermatitis7.5.2026 15:50:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced final 24-week data from the Phase 3 TRuE-AD4 study evaluating the efficacy and safety of Opzelura® (ruxolitinib) cream in adults with moderate atopic dermatitis (AD) who had an inadequate response, intolerance or contraindication to topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs). These data were presented (Abstract ID: P0851) today at the 2026 European Academy of Dermatology and Venereology (EADV) Symposium, being held May 7–9, 2026, in Athens, Greece. As previously reported, the TRuE-AD4 study met both of its co-primary endpoints at Week 8, with a statistically significantly higher proportion of patients on Opzelura versus vehicle cream achieving EASI75 (≥75% improvement in Eczema Area and Severity Index score from baseline) and, separately, IGA-TS (Investigator's Global Assessment Treatment Success, defined as an IGA score of 0 [clear] or 1 [almost clear] with at least a two-point improvement from baseline).1 Patients who
Rapid Medical™’s TIGERTRIEVER™ 13 Demonstrates Promising 90-Day Outcomes in DISTALS Trial, Reinforcing Pivotal Safety and Efficacy Findings7.5.2026 15:03:00 EEST | Press release
Rapid Medical™, a leading developer of advanced stroke treatment devices, today announced full results from the DISTALS randomized clinical trial, presented at the 11th European Stroke Organisation Conference (ESOC) in Maastricht, Netherlands, showing that TIGERTRIEVER™ 13 can safely restore blood flow to the brain and may improve clinical outcomes in patients with distal and medium vessel occlusion (DMVO) stroke. These findings build on earlier results showing a threefold improvement in restoring blood flow compared with medical management alone (p<0.0001), with no cases of serious brain bleeding observed in the treatment group. “These results show we can now safely restore blood flow and suggest this will make a meaningful difference for the right patients,” said Jeffrey L. Saver, MD, UCLA, and Principal Investigator of DISTALS. “What’s important is that both the device and the trial were designed specifically for distal stroke. By using a device built for these small vessels and mea
2 Million Downloads in Six Months: Tabelog’s Multilingual App Solves Critical Dining Pain Points for Travelers to Japan7.5.2026 15:00:00 EEST | Press release
Tabelog (https://tabelog.com/en/), one of Japan’s largest (*1) restaurant search and reservation services operated by Kakaku.com, Inc., has announced that its multilingual smartphone app (iOS/Android) for travelers visiting Japan has reached 2 million downloads (*2). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507560248/en/ 2M+ Downloads in 6 Months. The app also ranked #1 in downloads among Restaurant Search Apps in Japan for International Travelers (*3) in Taiwan, Hong Kong, South Korea, and the U.S., reflecting its immense popularity among global visitors. Download URL: https://tabelog-tourists.onelink.me/3eEh/iqkkho9r The Trusted Choice for Global Travelers: Solving Two Major Dining Pain Points in Japan For years, international visitors to Japan have faced two critical dining pain points: [Pain Point 1] The Information Gap: Most available resources are tailored for tourists, making it difficult to find the true loc
Altasciences and Certara Announce Strategic Partnership to Accelerate Early Drug Development7.5.2026 15:00:00 EEST | Press release
Altasciences, a fully integrated drug development solution company, andCertara (Nasdaq: CERT), a global leader in model-informed drug development (MIDD), today announced a strategic partnership to accelerate early-phase development programs. Fewer than half of preclinical drug candidates successfully reach first-in-human trials. Failures are driven by toxicity, poor pharmacokinetics, lack of efficacy, and challenges translating results from animals to humans. Many of these risks can be mitigated through a fully integrated model-informed drug development approach. Building on Altasciences’ Acceleration Platform, the integration of Certara’s strategic drug development services and biosimulation technology enables sponsors to establish proof of mechanism earlier, design more efficient studies, and make informed go/no-go decisions with greater confidence. By embedding modeling insights and digital workflows directly into development execution, study designs are optimized, dosing strategies
FIFA and Fanatics Expand Wide-Ranging Relationship to Include Historic Exclusive Collectibles Agreement (Trading Cards, Stickers and Trading Card Games)7.5.2026 14:00:00 EEST | Press release
In a landmark agreement expanding their already successful wide-ranging commercial relationship, FIFA and Fanatics have signed a long-term, exclusive collectibles licensing deal that features trading cards, stickers, and trading card games. The agreement, which will begin in full in 2031, covers both physical and digital collectibles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507105628/en/ An example of the product innovations that will be brought to fans under this new partnership is the highly sought-after player jersey patch program, including debut patches, which will be inserted into football trading cards from 2031 onward. All products will be designed and developed through Fanatics Collectibles and produced under the Topps brand. As a part of the deal, Fanatics will bring the magic to young people in every region of the world and support youth football globally by distributing more than $150 million in collect
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom